These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 18776936)

  • 21. Incorporation of a synthetic mycobacterial monomycoloyl glycerol analogue stabilizes dimethyldioctadecylammonium liposomes and potentiates their adjuvant effect in vivo.
    Nordly P; Korsholm KS; Pedersen EA; Khilji TS; Franzyk H; Jorgensen L; Nielsen HM; Agger EM; Foged C
    Eur J Pharm Biopharm; 2011 Jan; 77(1):89-98. PubMed ID: 20940050
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Type I IFN signalling is required for cationic adjuvant formulation (CAF)01-induced cellular immunity and mucosal priming.
    McEntee CP; Moran HBT; Muñoz-Wolf N; Liddicoat AM; Carroll EC; Erbo-Wern J; Coulter IS; Andersen P; Follmann F; Lavelle EC
    Vaccine; 2020 Jan; 38(3):635-643. PubMed ID: 31727505
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adsorption of protein antigen to the cationic liposome adjuvant CAF®01 is required for induction of Th1 and Th17 responses but not for antibody induction.
    Wørzner K; Hvannastein J; Schmidt ST; Foged C; Rosenkrands I; Pedersen GK; Christensen D
    Eur J Pharm Biopharm; 2021 Aug; 165():293-305. PubMed ID: 34044110
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Induction of CD8+ T-cell responses against subunit antigens by the novel cationic liposomal CAF09 adjuvant.
    Korsholm KS; Hansen J; Karlsen K; Filskov J; Mikkelsen M; Lindenstrøm T; Schmidt ST; Andersen P; Christensen D
    Vaccine; 2014 Jun; 32(31):3927-35. PubMed ID: 24877765
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Correlating liposomal adjuvant characteristics to in-vivo cell-mediated immunity using a novel Mycobacterium tuberculosis fusion protein: a multivariate analysis study.
    Kastner E; Hussain MJ; Bramwell VW; Christensen D; Perrie Y
    J Pharm Pharmacol; 2015 Mar; 67(3):450-63. PubMed ID: 25677402
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of a rapid in vitro pre-screen for distinguishing effective liposome-adjuvant delivery systems.
    Feather LAJ; Nadella V; Kastner E; Perrie Y; Hilton AC; Devitt A
    Sci Rep; 2022 Jul; 12(1):12448. PubMed ID: 35859154
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systematic Investigation of the Role of Surfactant Composition and Choice of oil: Design of a Nanoemulsion-Based Adjuvant Inducing Concomitant Humoral and CD4
    Schmidt ST; Neustrup MA; Harloff-Helleberg S; Korsholm KS; Rades T; Andersen P; Christensen D; Foged C
    Pharm Res; 2017 Aug; 34(8):1716-1727. PubMed ID: 28516400
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of incorporating cholesterol into DDA:TDB liposomal adjuvants on bilayer properties, biodistribution, and immune responses.
    Kaur R; Henriksen-Lacey M; Wilkhu J; Devitt A; Christensen D; Perrie Y
    Mol Pharm; 2014 Jan; 11(1):197-207. PubMed ID: 24171445
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A strong adjuvant based on glycol-chitosan-coated lipid-polymer hybrid nanoparticles potentiates mucosal immune responses against the recombinant Chlamydia trachomatis fusion antigen CTH522.
    Rose F; Wern JE; Gavins F; Andersen P; Follmann F; Foged C
    J Control Release; 2018 Feb; 271():88-97. PubMed ID: 29217176
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The vesicle size of DDA:TDB liposomal adjuvants plays a role in the cell-mediated immune response but has no significant effect on antibody production.
    Henriksen-Lacey M; Devitt A; Perrie Y
    J Control Release; 2011 Sep; 154(2):131-7. PubMed ID: 21640145
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CAF01 potentiates immune responses and efficacy of an inactivated influenza vaccine in ferrets.
    Martel CJ; Agger EM; Poulsen JJ; Hammer Jensen T; Andresen L; Christensen D; Nielsen LP; Blixenkrone-Møller M; Andersen P; Aasted B
    PLoS One; 2011; 6(8):e22891. PubMed ID: 21850242
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Subunit vaccines: distearoylphosphatidylcholine-based liposomes entrapping antigen offer a neutral alternative to dimethyldioctadecylammonium-based cationic liposomes as an adjuvant delivery system.
    McNeil SE; Rosenkrands I; Agger EM; Andersen P; Perrie Y
    J Pharm Sci; 2011 May; 100(5):1856-65. PubMed ID: 21374619
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transcriptomics of the Vaccine Immune Response: Priming With Adjuvant Modulates Recall Innate Responses After Boosting.
    Santoro F; Pettini E; Kazmin D; Ciabattini A; Fiorino F; Gilfillan GD; Evenroed IM; Andersen P; Pozzi G; Medaglini D
    Front Immunol; 2018; 9():1248. PubMed ID: 29922291
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influenza NG-34 T cell conserved epitope adjuvanted with CAF01 as a possible influenza vaccine candidate.
    Sisteré-Oró M; Pedersen GK; Córdoba L; López-Serrano S; Christensen D; Darji A
    Vet Res; 2020 Apr; 51(1):57. PubMed ID: 32312317
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of two different PEGylation strategies for the liposomal adjuvant CAF09: Towards induction of CTL responses upon subcutaneous vaccine administration.
    Schmidt ST; Olsen CL; Franzyk H; Wørzner K; Korsholm KS; Rades T; Andersen P; Foged C; Christensen D
    Eur J Pharm Biopharm; 2019 Jul; 140():29-39. PubMed ID: 31055066
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting the Mincle and TLR3 receptor using the dual agonist cationic adjuvant formulation 9 (CAF09) induces humoral and polyfunctional memory T cell responses in calves.
    Thakur A; Andrea A; Mikkelsen H; Woodworth JS; Andersen P; Jungersen G; Aagaard C
    PLoS One; 2018; 13(7):e0201253. PubMed ID: 30063728
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design of Gadoteridol-Loaded Cationic Liposomal Adjuvant CAF01 for MRI of Lung Deposition of Intrapulmonary Administered Particles.
    Thakur A; Rose F; Ansari SR; Koch P; Martini V; Ovesen SL; Quistorff B; Maritim S; Hyder F; Andersen P; Christensen D; Mori Y; Foged C
    Mol Pharm; 2019 Nov; 16(11):4725-4737. PubMed ID: 31539263
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nano-Self-Assemblies Based on Synthetic Analogues of Mycobacterial Monomycoloyl Glycerol and DDA: Supramolecular Structure and Adjuvant Efficacy.
    Martin-Bertelsen B; Korsholm KS; Roces CB; Nielsen MH; Christensen D; Franzyk H; Yaghmur A; Foged C
    Mol Pharm; 2016 Aug; 13(8):2771-81. PubMed ID: 27377146
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CAF05: cationic liposomes that incorporate synthetic cord factor and poly(I:C) induce CTL immunity and reduce tumor burden in mice.
    Hansen J; Lindenstrøm T; Lindberg-Levin J; Aagaard C; Andersen P; Agger EM
    Cancer Immunol Immunother; 2012 Jun; 61(6):893-903. PubMed ID: 22095092
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Heterologous Prime-Boost Combinations Highlight the Crucial Role of Adjuvant in Priming the Immune System.
    Ciabattini A; Pettini E; Fiorino F; Lucchesi S; Pastore G; Brunetti J; Santoro F; Andersen P; Bracci L; Pozzi G; Medaglini D
    Front Immunol; 2018; 9():380. PubMed ID: 29593710
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.